Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

A Two-Year Observational Follow-up Study of Subjects With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control

To see complete record on, please visit this link

Id: NCT04353921

Organisation Name: Usona Institute

Overal Status: Enrolling by invitation

Start Date: June 30, 2020

Last Update: November 1, 2022

Lead Sponsor: Usona Institute

Brief Summary: This is a Phase 2 double-blind, long-term observational follow-up study of participants from Study PSIL201. Participants providing informed consent will be enrolled into this study and will complete web surveys and telephone interviews conducted by one central site at the following time intervals: months 2, 3, 4, 5 and 6 (± 7 days for each assessment) and months 8, 10, 12, 14, 16, 18, 20, 22 and 24 (± 14 days for each assessment).

  • Major Depressive Disorder

Total execution time in seconds: 0.48659920692444